nach oben

Drug Safety

Erschienen in:

01.11.2000 | Review Article

Risks and Benefits of Therapies for Apnoea in Premature Infants

verfasst von: Dr Jean-Michel Hascoet, Isabelle Hamon, Marie-Jeanne Boutroy

Erschienen in: Drug Safety | Ausgabe 5/2000

Einloggen, um Zugang zu erhalten

Abstract

Apnoea in infants can result from a wide range of causes, and requires thorough evaluation before deciding on appropriate treatment. Continuous monitoring of premature infants with apnoea is mandatory in order to define the pathophysiology and type of apnoea; selection of treatment involves careful assessment of aetiology, as well as efficacy and tolerability in each individual case. The objective of treatment is to prevent the deleterious consequences of apnoeas that last >20 seconds and/or are associated with bradycardia, cyanosis or pallor, and occur more often than once an hour over a 12-hour period.

Apnoea management involves both pharmacological and nonpharmacological treatment. We suggest methylxanthines as first-line therapy for idiopathic apnoeas; evidence suggests that caffeine is better tolerated and as efficacious as theophylline (since it is particularly efficacious against the ‘central’ component of idiopathic apnoea of prematurity). If treatment fails, additional measures such as doxapram may be appropriate when hypoventilation is present, or nasal continuous positive airway pressure when upper airway instability or obstructive apnoeas are predominant. Apnoea prophylaxis is an additional reason to advocate prenatal maturation with betamethasone. Weaning from treatment is attempted 4 to 5 days after complete resolution of apnoea, beginning with the last treatment introduced. Monitoring should be maintained for 4 to 5 days to detect any relapse of recurrent and severe apnoeas, which would lead to the resumption of the most recently withdrawn treatment.

Marchal F, Bairam A, Vert P. Neonatal apnea and apneic syndromes. Clin Perinat 1987; 509-29

Cheung PY, Barrington KJ, Finer NN, et al. Early childhood neurodevelopment in very low birth weight infant with predischarge apnea. Pediatr Pulmonol 1999; 27: 14–20PubMed

Deykin A, Bauman ML, Kelly DH, et al. Apnea of infancy and subsequent neurologic, cognitive, and behavioral status. Pediatrics 1984; 73: 638–45PubMed

Martin RJ, Fanaroff AA. Neonatal apnea, bradycardia, or desaturation: Does it matter? J Pediatr 1998; 132: 758–9PubMed

Hascoët JM, Boutroy MJ. Traitement des apnées du prématuré. Arch Pediatr 1998; 5: 546–52PubMed

Gaultier C, Curzi-Dascalova L. Apnées et bradycardies du prématuré In: Relier JP, editor. Progres en néonatalogie. Paris: Karger, 1996; 16: 33–42

Gaultier C. Physiopathologie des bradycardies du nourrisson. Arch Pediatr 1994; 1: 389–91PubMed

Martin RJ, DiFiore JM, Jana L, et al. Persistence of the biphasic ventilatory response to hypoxia in preterm infants. J Pediatr 1998; 132: 960–64PubMed

Adams JA, Zabaleta IA, Sackner MA. Hypoxemic events in spontaneously breathing premature infants: etiologic basis. Pediatr Res 1997; 42: 463–71PubMed

10.

Hascoet JM, Parker RA, Lindstrom DP, et al. Short apnea status in the thriving preterm newborn: effect on cerebral circulation [abstract]. Pediatr Res 1989; 25: 1288 A

11.

Jenni OG, Wolf M, Hengartner M, et al. Impact of central, obstructive and mixed apnea on cerebral hemodynamics in preterm infants. Biol Neonate 1996; 70: 91–100PubMed

12.

Perlman J, Volpe J. Episodes of apneoa and bradycardia in the preterm newborn: impact on cerebral circulation. Pediatrics 1985; 76: 333–8PubMed

13.

Saliba E, Favre A, Lac L, et al. Retentissement des apnées et bradycardies du prématuré sur l’hemodynamique cérébrale et l’EEG. In: Relier JP, editor. Progrès en néonatalogie. Paris: Karger, 1996; 16: 43–51

14.

Urlesberger B, Kaspirek A, Pichler G, et al. Apnoea of prematurity and changes in cerebral oxygenation and cerebral blood volume. Neuropediatrics 1999; 30: 29–33PubMed

15.

Miller MJ, Petrie TG, Difiore JM. Changes in resistance and ventilatory timing that accompany apnea in premature infants. J Appl Physiol 1993; 75: 720–3PubMed

16.

Poets CF, Stebbens VA, Samuels MP, et al. The relationship between bradycardia, apnea and hypoxemia in preterm infants. Pediatr Res 1993; 34: 144–7PubMed

17.

Idiong N, Lemke RP, Lin YJ, et al. Airway closure during mixed apneas in preterm infants: is respiratory effort necessary? J Pediatr 1998; 133: 509–12PubMed

18.

Upton CJ, Milner AD, Stokes GM. Upper airway patency during apnoea of prematurity. Arch Dis Child 1992; 67: 419–24PubMed

19.

Finer NN, Barrington K. Respiratory effort with airway closure during mixed apneas. J Pediatr 1999; 134: 796–97PubMed

20.

Idiong N, Rigatto H. Respiratory effort with airway closure during mixed apneas. J Pediatr 1999; 134: 797–98PubMed

21.

Hanam S, Ingram DM, Milner AD. A possible role for the Hering-Breuer deflation reflex in apnea of prematurity. J Pediatr; 132: 35–9

22.

Moriette G. Apnees du nouveau-né. In: iRelier JP, Laugier J, Salle BL, editors. Medecine Perinatale. Paris: Flammarion Medecine-Sciences, 1990: 329–34

23.

Lindgren C, Grogaard J. Reflex apnea response and inflammatory mediators in infants with respiratory tract infection. Acta Paediatr 1996; 85: 798–803PubMed

24.

Saxena A, Sharma M, Kothari SS, et al. Prostaglandin E1 in infants with congenital heart disease: Indian experience. Indian Pediatr 1998; 35: 1063–9PubMed

25.

Tudehope DI, Rogers Y. Clinical spectrum of neonatal apnoea in very low birthweight infants. Aust Paediatr J 1984; 20: 131–5PubMed

26.

Sheikh S, Stephen TC, Sisson B. Prevalence of gastrooesophageal reflux in infants with recurrent brief apneic episodes. Can Respr J 1999; 6: 401–4

27.

Marcus CL, Hamer A. Significance of isolated bradycardia detected by home monitoring. J Pediatr 1999; 135: 321–6PubMed

28.

Benz RL, Pressman MR, Hovick ET, et al. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients. Am J Kidney Dis 1999; 34: 1089–95PubMed

29.

Sasidharan P, Heimler R. Transfusion-induced changes in the breathing pattern of healthy preterm anemic infants. Pediatr Pulmonol 1992; 12: 170–3PubMed

30.

Lander J, Brady-Fryer B, Metcalfe JB, et al. Comparison of ring block, dorsal penile nerve block, and topical anesthesia for neonatal circumcision: a randomized controlled trial. JAMA 1997; 278: 2157–62PubMed

31.

Coit AK. Necrotizing enterocolitis. J Perinat Neonatal Nurs 1999; 12: 53–66PubMed

32.

Gunn TR, Tonkin SL, Hadden W, et al. Neonatal micrognathia is associated with small upper airways on radiographic measurement. Acta Paediatr 2000; 89: 82–7PubMed

33.

Kahn A, Groswasser J, Sottiaux M, et al. Mechanisms of obstructive sleep apneas in infants. Biol Neonate 1994; 65: 235–9PubMed

34.

Avanzini A, Colombo T, Vitali GM, et al. Peristent bradycardia and apnea due to hypothyroidism in a very low birth weight newborn infant. Minerva Pediatr 1991; 43: 461–4PubMed

35.

Martinez-Bermejo A, Roche C, Lopez-Martin V, et al. Clinical significance of episodes of apnea in babies. Rev Neurol 1997; 25: 545–7PubMed

36.

Gerchanik JJ, Levkoff AH; Duncan R. The association of hypocalcemia and recurrent apnea in premature infants. Am J Obstet Gynecol 1972; 113: 646–52

37.

Daily WJR, Klaus M, Meyer HBP. Apnea in premature infants: monitoring incidence, heart rate changes and an effect of environmental temperature. Pediatrics 1969; 43: 510–8PubMed

38.

Koons AH. Neurodevelopmental outcome in infants with apnea. N J Med 1992; 89: 688–90PubMed

39.

American Academy of Pediatrics. Task force on prolonged apnoea: prolonged infantile apnoea 1985. Pediatrics 1985; 76: 129–31

40.

Razi NM, Humphreys J, Pandit PB, et al. Predischarge monitoring of preterm infants. Pediatr Pulmonol 1999; 27: 113–6PubMed

41.

Vogl A. Euphyllin. Wien Klin Wochenschr 1927; 40: 105–8

42.

Kuzemko JA, Paala J. Apnoeic attacks in the newborn treated with aminophylline. Arch Dis Child 1973; 48: 404–6PubMed

43.

Maxwell DL, Fuller RW, Conradson TB, et al. Contrasting effects of two xanthines, theophylline and enprofylline, on the cardio-respiratory stimulation of infused adenosine in man. Acta Physiol Scand 1987; 131: 459–65PubMed

44.

Davi MJ, Sankaran K, Simons KJ, et al. Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. J Pediatr 1978; 92: 91–5PubMed

45.

Shannon DC, Gotay F, Stein IM, et al. Prevention of apnea and bradycardia in low-birthweight infants. Pediatrics 1975; 55:589–94PubMed

46.

Uauy R, Shapiro DL, Smith B, et al. Treatment of severe apnea in prematures with orally administered theophylline. Pediatrics 1975; 55: 595–8PubMed

47.

Bednarek EJ, Roloff DW. Treatment of apnea of prematurity with aminophylline. Pediatrics 1975; 58: 335–9

48.

Peabody JL, Neese AL; Alister GS, et al. Transcutaneous oxygen monitoring in aminophylline-treated apneic infants. Pediatrics 1978; 62: 698–701PubMed

49.

Peliowski A, Finer NN. A blinded, randomized, placebo-controlled trial to compare theophylline and doxapram for the treatment of apnea of prematurity. J Pediatr 1990; 116: 648–53PubMed

50.

Aranda JV. Methylxanthines in apnea of prematurity. Clin Perinatol 1979; 6: 87–108PubMed

51.

Aranda JV, Gorman W, Bergsteinsson H, et al. Efficacy of caffeine in treatment of apnea in the low-birthweight infant. J Pediatr 1977; 90: 467–72PubMed

52.

Gunn TR. Sequelae of caffeine treatment in preterm infants with apnea. J Pediatr 1979; 94: 106–9PubMed

53.

Bairam A, Boutroy MJ, Badonnel Y, et al. Theophylline versus caffeine: comparative effects of treatment of idiopathic apnea in the preterm infant. J Pediatr 1987; 110: 636–9PubMed

54.

Scanlon JEM, Chin KC, Morgan MEI, et al. Caffeine or theophylline for neonatal apnea? Am J Dis Child 1992; 67: 425–8

55.

Aranda JV, Cook CE, Gorman W, et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr 1979; 94: 663–8PubMed

56.

Fuglsang G, Nielsen K, Kjoer Nielsen L, et al. The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants. Acta Paediatr Scand 1989; 78: 786–8PubMed

57.

Lee TC, Charles B, Steer P, et al. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther 1997; 61: 628–40PubMed

58.

Stephenson T. Caffeine for neonates. Paed Perinat Drug Ther 1997; 1: 46–9

59.

Boutroy MJ, Vert P, Royer RJ, et al. Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant. J Pediatr 1979; 94: 996–8PubMed

60.

Gorodischer R, Karplus M. Pharmacokinetic aspects of caffeine in premature infants with apnea. Eur J Clin Pharmacol 1982; 22: 47–52PubMed

61.

Walther FJ; Erickson R, Sims ME. Cardiovascular effects of caffeine therapy in preterm infants. Am J Dis Child 1990; 144: 1164–6PubMed

62.

Skopnick H, Koch G, Heimann G. Effects of methylxanthines on periodic respiration and acid gastro-oesophageal reflux in newborn infants. Monatschr Kinderheilkd 1990; 138: 123–7

63.

Vandenplas Y, De Wolf D, Sacre L. Influence of xanthines in gastrooesophageal reflux in infants at risk for sudden death syndrom. Pediatrics 1986; 77: 807–10PubMed

64.

Novicki PT. Methylxanthines and necrotizing enterocolitis revisited. J Pediatr Gastro Enterol Nutr 1989; 9: 137–8

65.

Kulkarni PB, Dorand RD. Caffeine toxicity in a neonate. Pediatrics 1979; 64: 254–5PubMed

66.

Banner W, Czajka PA. Acute caffeine overdose in the neonate. Arch Dis Child 1980; 134: 495–8

67.

Van Den Anker JN, Jongejan HT, Saver PJJ. Severe caffeine intoxication in a preterm neonate. Eur J Pediatr 1992; 151: 466–8 LPubMed

68.

Bory C, Balthassat P, Porthault M, et al. Metabolism of theophylline to caffeine in premature newborn infants. J Pediatr 1979; 94: 988–92PubMed

69.

Wechsler RL, Kleiss LM, Kety SS. The effects of intravenous administered aminophylline on cerebral circulation and metabolism in man. J Clin Invet 1950; 29: 28–30

70.

Cameron OG, Modell JG, Hariharan M. Caffeine and human cerebral blood flow: a position emission tomography study. Life Sci 1990; 47: 1141–6PubMed

71.

Lundstrom KE, Larsen PS, Brendstrup L, et al. Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or theophylline. Acta Paediatr 1995; 84: 6–9PubMed

72.

Saliba E, Autret E, Gold F, et al. Caffeine and cerebral blood flow velocity in preterm infants. Dev Pharmacol Ther 1989; 13: 134–8PubMed

73.

Van Bel F, Van de Bor M, Stijnen T, et al. Does caffeine affect cerebral blood flow in preterm infant? Acta Paediatr Scand 1989; 78: 205–9PubMed

74.

Rubio R, Berne R, Bockman EL, et al. Relationship between adenosine concentration and oxygen supply in rat brain. Am J Physiol 1975; 228: 1896–1902PubMed

75.

Daval JL, Nicolas F. Opposite effects of cyclohexyladenosine and theophylline on hypoxic damage in cultured neurons. Neurosci Lett 1994; 175: 114–6PubMed

76.

Barnes AR, Hebron BS, Smith J. Stability of caffeine oral formulations for neonatal use. J Clin Pharmacol Ther 1994; 19: 391–6

77.

Burki NK. Ventilatory effects of doxapram in conscious human subjects. Chest 1984; 85: 604–8

78.

Tay-Uyboco J, Kwiatkowski K, Cates D, et al. Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity. Biol Neonate 1991; 59: 190–200PubMed

79.

Bairam A, Faulon M, Monin P, et al. Doxapram for the initial treatment of idiopathic apnea of prematurity. Biol Neonate 1992; 61: 1209–13

80.

Wasserman AJ, Richardson DW. Human cardiopulmonary effects of doxapram, a cardiorespiratory stimulant. Clin Pharmacol Ther 1963; 4: 321–5PubMed

81.

Kato H, Buckley JP. Possible sites of action of the respiratory stimulant effect of doxapramhydrochloride. J Pharmacol Exp Ther 1964; 144: 260–4PubMed

82.

Funderburk WH, Alphin RS. Electrical changes in the CNS produced by a new respiratory stimulant AHR-619. Fed Proc 1962; 21: 324–6

83.

Bairam A, Blanchard PW, Mullahoo K, et al. Pharmacodynamic effects and pharmacokinetic profiles of keto-doxapram and doxapram in newborn lambs. Pediatr Res 1990; 28: 142–6PubMed

84.

Sasaki KI, Furusawa S, Takayanagi G. Effect of doxapram on the action of the other drugs and the hepatic drug-metabolizing system in mice. Japan J Pharmacol 1982; 32: 699–707

85.

Ishikawa M, Osaki M, Takayanagi Y, et al. Induction of hepatic P450 and drug metabolism by doxapram in the mouse. Res Com Chem Pathol Pharmacol 1991; 72: 109–12

86.

Jamali F, Coutts RT, Malek F, et al. Lack of a pharmacokinetic interaction between doxapram and theophylline in apnea of prematurity. Dev Pharmacol Ther 1991; 16: 78–82PubMed

87.

Polleri JO, Zambosco AL, Muchada R. Dopram as a pharmacological ventilator in respiratory depression in newborn. Dia Med Uruguayo 1969; 36: 439–40

88.

Gupta PK, Moore J. The use of doxapram in the newborn. J Obstet Gynaecol Br Comm 1973; 80: 1002–6

89.

Burnard ED, Moore RG, Nichol H. A trial of doxapram in the recurrent apnea of prematurity. In: Stern L, Oh W, Friis-Hansen B, editors. Intensive care in the newborn II. New York (NY): Masson Press, 1978: 143–8

90.

Hunt CE, Inwood RJ, Shannon DC. Respiratory and non respiratory effects of doxapram in congenital central hypoventilation syndrome. Am Rev Respir Dis 1979; 119: 263–6PubMed

91.

Barrington KJ, Finer NN, Peters KL, et al. Physiologic effects of doxapram in idiopathic apnea of prematurity. J Pediatr 1986; 108: 125–9

92.

Hayakawa F, Hakakawa S, Kuno K, et al. Doxapram in the treatment of idiopathic apnea of prematurity: desirable dosage and serum concentration. J Pediatr 1986; 109: 138–40PubMed

93.

Barrington KJ, Finer NN, Torok-Both, et al. Dose-response relationship of doxapramin the therapy for refractory idiopathic apnea of prematurity. Pediatrics 1987; 80: 22–7PubMed

94.

Huon C, Rey E, Mussat P, et al. Low-dose doxapram for treatment of apnoea following early weaning in very low birthweight infants: a randomized, double-blind study. Acta Pædiatr 1998; 87: 1180–4PubMed

95.

Barrington KJ, Muttit SC. Randomized, controlled, blinded trial of doxapram for extubation of the very low birthweight infant. Acta Paediatr 1998; 87: 191–4PubMed

96.

Jamali F, Barringon KJ, Finer NN, et al. Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data. Dev Pharmacol Ther 1988; 11: 253–7PubMed

97.

Kumita H, Mizuno S, Shinohara M, et al. Low-dose doxapram therapy in premature infants and its CSF and serum concentrations. Acta Paediatr Scand 1991; 80: 786–91PubMed

98.

Sagi E, Eyal F, Alpan G, et al. Idiopathic apnoea of prematurity treated with doxapram and aminophylline. Arch Dis Child 1984; 59: 281–3PubMed

99.

Dear PRF, Wheeler D. Doxapram and neonatal apnoea. Arch Dis Child 1984; 59: 903–4PubMed

100.

Beaudry M, Bradley JM, Gramlich LM, et al. Pharmacokinetics of doxapram in idiopathic apnea of prematurity. Dev Pharmacol Ther 1988; 11: 65–72PubMed

101.

Barbé F, Hansen C, Badonnel Y, et al. Severe side effects and drug plasma concentrations in preterm infants treated with doxapram. Ther Drug Monitor 1999; 21: 547–52

102.

Boutroy MJ, Dalati M, Barbé F, et al. Doxapram per os: an alternative to IV infusion in treating apnea of prematurity? [abstract]. Pediatr Res 1994; 35(4): 82A

103.

De Villiers GS, Walele A, Van der Merwe PL, et al. Second degree atrioventicular heart block after doxapram administration. J Pediatr 1998; 133: 149–50PubMed

104.

Poets C, Darraj S, Bohnhorst B. Effect of doxapramon episodes of apnoea, bradycardia and hypoxemia in preterm infants. Biol Neonate 1999; 76: 207–13PubMed

105.

Bairam A, Akramoff-Gershan L, Beharry K, et al. Gastrointestinal absorption of doxapram in neonates. Am J Perinatol 1991; 8: 110–3PubMed

106.

Bairam A, Beharry K, Laudignon N, et al. Doxapram metabolism in human fetal hepatic organ culture. Clin Pharmacol Ther 1991; 50: 32–8PubMed

107.

Robson RH, Prescott LF. Rapid gas-liquid chromatographic estimation of doxapram in plasma. J Chromatogr 1977; 143: 527–9PubMed

108.

Gershanik JJ, Boeder G, Ensley H, et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 1982; 307: 1384–8PubMed

109.

Jackson D. Reply to: Doxapram and potential benzyl alcohol toxicity: a moratorium on clinical investigation? [letter]. Pediatrics 1986; 78: 541

110.

Weesner KM, Boyle RJ. Successful management of central sleep hypoventilation in an infant using enteral doxapram. J Pediatr 1985; 106: 513–5PubMed

111.

Jordan GD, Themelis NJ, Messerly SO, et al. Doxapram and potential benzyl alcohol toxicity: a moratorium on clinical investigation? Pediatrics 1986; 78: 540–1PubMed

112.

Angell C, Carbine T, Hiatt M, et al. Prenatal betamethasone and apnea in preterm infants [abstract]. Pediatr Res 1997; 41: 136A

113.

Winchester PD, Secory A. Prenatal betamethasone effects on postmenstrual age at last apnea and discharge in preterm infants [abstract]. Pediatr Res 1999; 45: 233A

114.

Amorim MM, Santos LC, Faundes A. Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1283–8PubMed

115.

Baud O, Foix-L’Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999; 341: 1190–6PubMed

116.

Elimina A, Verma U, Canterino J, et al. Effectiveness of antenatal steroids in obstetric subgroups. Obstet Gynecol 1999; 93: 174–9

117.

Pratt L, Waschbusch L, Ladd W, et al. Multiple vs single betamethasone therapy. Neonatal and maternal effect. J Reprod Med 1999; 44: 257–64PubMed

118.

Jobe AH, Newnham J, Willet K, et al. Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids. Pediatrics 1998; 102: 1116–25PubMed

119.

Yunis KA, Bitar FF, Hayek P, et al. Transient hypertrophic cardiomyopathy in the newborn following multiple doses of antenatal corticosteroids. Am J Perinatol 1999; 16: 17–21PubMed

120.

Cordoba E, Gerhardt T, Rojas M, et al. Comparison of the effects of acetazolamide and aminophylline on apnea incidence and on ventilatory response to CO2 in preterm infants. Pediatr Pulmonol 1994; 17: 291–5PubMed

121.

Miller CA, Gaylord M, Lorch M, et al. The use of primidone in neonates with theophylline-resistant apnea. Am J Dis Child 1993; 147: 183–186PubMed

122.

Sapin Jl, Riviero JJ, Grover WD. Efficacy of primidone for seizure control in neonates and young infants. Pediatr Neurol 1988; 4: 292–5PubMed

123.

Blond MH, Luksenberg S, Rondeau-Desperiez C, et al. Apnées, bradycardies et malaises précoces du nouveau-né prématuré. In: Relier JP, editor. Progrès en néonatalogie. Paris: Karger, 1996; 16: 52–65

124.

Agence du médicament, direction de l’Evaluation. Information des prescripteurs sur l’utilisation du Prantal®. Arch Pediatr 1997; 4: 78–80

125.

Bennasr S, Baumann C, Casadevall I, et al. Bloc auriculo-ventriculaire compliquant l’utilisation du diphémanil (Prantal) chez deux nouveau-nés prématurés. Arch Fr Pediatr 1993; 50: 413–5PubMed

126.

Kattwinkel J, Fanaroff AA, Klaus MH. Bradycardia in preterm infants: indications and hazards of atropine therapy. Pediatrics 1976; 58: 494–9PubMed

127.

Pariente-Khayat A, Vidal AM, Cheron G, et al. Pharmacokinetics of diphemanil methylsulfate in neonates and in premature infants. Eur J Clin Pharmacol 1996; 50(5): 429–30PubMed

128.

Wagaman MJ, Shutack JG, Moomjian AS. Improved oxygenation and lung compliance with prone positioning of neonates. J Pediatr 1979; 94: 787–91PubMed

129.

Hewitt VM. Effect of posture on the presence of fat in tracheal aspirate in neonates. Aust Paediatr J 1976; 12: 267–71PubMed

130.

Goto K, Mirmira M, Adam M, et al. More awakenings and heart rate variability during supine sleep in preterm infants. Pediatrics 1999; 103: 603–9PubMed

131.

Jenni OG, von Siebenthal K, Wolf M, et al. Effect of nursing in the head elevated tilt position (15°) on the incidence of bradycardic and hypoxemic episodes in preterm infants. Pediatrics 1997; 100: 622–5PubMed

132.

Keene DJ, Wimmer JE, Mathew OP. Does supine positioning increase apnea, bradycardia, and desaturation in preterm infants J Perinatol 2000; 1: 17–20

133.

Berterottiere D, D’Allest AM, Dehan M, et al. Effects of increase in body temperature on the breathing pattern in premature infants. J Dev Physiol 1990; 13: 303–8PubMed

134.

Kumada M, Dampey RA, Reis DJ. The trigeminal depressor response: a novel vasodepressor response originating from the trigeminal system. Brain Res 1977; 119: 305–26PubMed

135.

Mac Culloch PF, Faber KM, Panneton WM. Electrical stimulation of the anterior ethmoidal nerve produces the diving response. Brain Res 1999; 830: 24–31

136.

Kattwinkel J, Nearman HS, Fanaroff AA, et al. Apnea of prematurity. Comparative therapeutic effects of cutaneous stimulation and nasal continuous positive airway pressure. J Pediatr 1975; 86: 588–92PubMed

137.

Andreasson B, Lindroth M, Svenningsen NW, et al. Effects on respiration of CPAP immediately after extubation in the very preterm infant. Pediatr Pulmonol 1988; 4: 213–8PubMed

138.

Robertson NJ, Hamilton PA. Randomised trial of elective continuous positive airway pressure (CPAP) compared with rescue CPAP after extubation. Arch Dis Child Fetal Neonatal Ed 1998; 79: F58–F60PubMed

139.

Jonsson B, Katz-Salamon M, Faxelius G, et al. Neonatal care of very-low-birthweight infants in special-care units and neonatal intensive-care units in Stockholm. Early nasal continuous positive airway pressure versus mechanical ventilation: gains and losses. Acta Paediatr 1997; 419: 4–10

140.

Roberton NR. Early nasal CPAP reduces the need for intubation in VLBM infants. Eur J Pediatr 1998; 157: 438PubMed

141.

Tapia JL, Bancalari A, Gonzalez A, et al. Does continuous positive airway pressure during weaning from intermittent mandatory ventilation in very low birth weight infants have risks or benefits? A controlled trial. Pediatr Pulmonol 1995; 19: 269–74PubMed

142.

Kurz H. Influence of nasopharyngeal CPAP on breathing pattern and incidence of apnoeas in preterm infants. Biol Neonate 1999; 76: 129–33PubMed

143.

Miller MJ, Carlo WA, Martin RJ. Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants. J Pediatr 1985; 106: 91–4PubMed

144.

Mac Namara F, Sullivan CE. Obstructive sleep apnea in infants and its management with nasal continuous positive airway pressure. Chest 1999; 116: 10–6

145.

Hagan R, Bryan AC, Bryan M, et al. Neonatal chest wall afferents and regulation of respiration. J Appl Physiol 1977; 42: 362–6PubMed

146.

Miller RW, Pollack MM, Murphy TM, et al. Effectiveness of continuous positive airway pressure in the treatment of bronchomalacia in infants: a bronchoscopic documentation. Crit Care Med 1986; 14: 125–7PubMed

147.

Durand M, Mc Cann E, Brady JP. Effect of continuous positive airway pressure on the ventilatory response to CO2 in preterm infants. Pediatrics 1983; 71: 634–8PubMed

148.

Moa G, Nilsson K. Nasal continuous positive airway pressure: experiences with a new technical approach. Acta Paediatr 1993; 82: 210–11PubMed

149.

Marshall TA, Deeder R, Pai S, et al. Physiologic changes associated with endotracheal intubation in preterm infants. Crit Care Med 1984; 12: 501–3PubMed

150.

Jarreau PH, Farhat M, Desfrere L, et al. Nouvelles modalites d’utilisation de la PEP nasale In: Relier JP, editor. Progres en neonatalogie. Paris: Karger, 1996; 16: 110–118

151.

Klausner JF, Lee AY, Hutchinson AA. Decreased imposed work with a new nasal continuous positive airway pressure device. Pediatr Pulmonol 1996; 22: 188–94PubMed

152.

Ahluwalia JS, White DK, Morley CJ. Infant flow driver or single prong nasal continuous positive airway pressure: short-term physiological effects. Acta Paediatr 1998; 87: 325–27PubMed

153.

Telenko T, Peliowski A, Hudson-Mason A. CPAP in the treatment of apnea of prematurity: comparison of 2 CPAP delivery systems [abstract]. Pediatr Res 1999; 45: 288A

154.

Roberton NR. Does CPAP work when it really matters? Acta Paediatr 1993; 82: 206–7PubMed

155.

Locke RG, Wolfson MR, Shaffer TH, et al. Inadvertent administration of positive end-distending pressure during nasal cannula flow. Pediatrics 1993; 91: 135–8PubMed

156.

Alpan G, Goder K, Glick B, et al. Pneumopericardium during continuous positive airway pressure in respiratory distress syndrome. Crit Care Med 1984; 12: 1080–1PubMed

157.

Hall RT, Rhodes PG. Pneumothorax and pneumomediastinum in infants with idiopathic respiratory distress syndrome receiving continuous airway pressure. Pediatrics 1975; 55: 493–6PubMed

158.

Wong W, Fok TF, Ng PC, et al. Vascular air embolism: a rare complication of nasal CPAP. J Paediatr Child Health 1997; 33: 444–5PubMed

159.

Hsu HS, Chen W, Wang NK. Effect of continuous positive airway pressure on cardiac output in neonates. Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1996; 37: 353–6PubMed

160.

Loftus BC, Ahn J, Haddad J Jr. Neonatal nasal deformities secondary to nasal continuous positive airway pressure. Laryngoscope 1994; 104: 1019–22PubMed

161.

Moloney G, Tudehope DI. Severe choanal stenosis complicating nasopharyngeal CPAP. J Paediatr Child Health 1993; 29: 72PubMed

162.

Abdel-Hady H, Mohareb S, Khashaba M, et al. Randomized controlled trial of discontinuation of nasal-CPAP in stable preterm infants breathing room air. Acta Paediatr 1998; 87: 82–7PubMed

163.

Claris O, Salle BL, Lapillonne A, et al. Nouvelle technique de pression positive continue par voie nasale en neonatologie. Arch Pediatr 1996; 3: 452–6PubMed

164.

Jaile JC, Levin T, Wung JT, et al. Benign gaseous distension of the bowel in premature infants treated with nasal continuous airway pressure: a study of contributing factors. AJR Am J Roentgenol 1992; 158: 125–7PubMed

165.

Svenningsen NW, Andreasson B, Lindroth M. Diuresis and urine concentration during CPAP in newborn infants. Acta Paediatr Scand 1984; 73: 727–32PubMed

166.

Tulassay T, Machay T, Kiszel J, Varga J. Effect of continuous positive airway pressure on renal function in prematures. Biol Neonate 1983; 43: 152–7PubMed

167.

Cowan F, Thoresen M. The effects of intermittent positive pressure ventilation on cerebral arterial and venous blood velocities in the newborn infant. Acta Paediatr Scand 1987; 76: 239–47PubMed

168.

Harding JE, Miles FKI, Becroft DMO, et al. Chest physiotherapy may be associated with brain damage in extremely premature infants. J Pediatr 1998; 132: 440–4PubMed

Titel: Risks and Benefits of Therapies for Apnoea in Premature Infants
verfasst von: Dr Jean-Michel Hascoet
Isabelle Hamon
Marie-Jeanne Boutroy
Publikationsdatum: 01.11.2000
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 5/2000
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200023050-00002

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2000

Thrombolytics

Antiandrogen Withdrawal Syndrome Associated with Prostate Cancer Therapies

Comparative Tolerability of Treatments for Inflammatory Bowel Disease

Risks and Benefits of Taxanes in Breast and Ovarian Cancer

Risks and Benefits of Preoperative High Dose Methylprednisolone in Surgical Patients

Chinese Proprietary Medicine in Singapore